OTS193320

OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX[1].

Product Specifications

CAS Number

[2093401-33-1]

UNSPSC

12352005

Hazard Statement

H315-H319

Target

Apoptosis; Histone Methyltransferase

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ots193320.html

Purity

99.08

Solubility

DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=[N+](C1=CC=C(CN[C@@H]2CC[C@H](NC3=CC4=NC(C5=CC(Cl)=C(OC)C=C5OC)=CN4C=C3)CC2)C=C1)[O-]

Molecular Formula

C28H30ClN5O4

Molecular Weight

536.02

Precautions

P264-P280-P302+P352-P305+P351+P338-P362+P364

References & Citations

[1]Theodore Vougiouklakis, et al. Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX. Oncotarget. 2018 Aug 7;9 (61) :31820-31831.